CAM
DNA icon

Close Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Close Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28
Closed – – 257
2025
Q1 		$0 Hold
28
– – ﹤0.01% 255
2024
Q4 		$0 Hold
28
– – ﹤0.01% 249
2024
Q3 		$0 Hold
28
– – ﹤0.01% 266
2024
Q2 		$0 Hold
28
– – ﹤0.01% 270
2024
Q1 		$1K Hold
28
– – ﹤0.01% 250
2023
Q4 		$2K Hold
28
– – ﹤0.01% 231
2023
Q3 		$2K Buy
+28
New +$2.24K ﹤0.01% 224
2023
Q2 		– Sell
-55
Closed -$3K – 255
2023
Q1 		$3K Hold
55
– – ﹤0.01% 218
2022
Q4 		$4K Hold
55
– – ﹤0.01% 183
2022
Q3 		$7K Hold
55
– – ﹤0.01% 163
2022
Q2 		$5K Hold
55
– – ﹤0.01% 171
2022
Q1 		$18K Hold
55
– – ﹤0.01% 172
2021
Q4 		$18K Hold
55
– – ﹤0.01% 172
2021
Q3 		$25K Buy
+55
New +$26.8K ﹤0.01% 158

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Close Asset Management's DNA Position: Q2 2025 in Review

Close Asset Management sold out of Ginkgo Bioworks (DNA) in Q2 2025, closing a stake of 28 shares.

Close Asset Management first reported a position in DNA in Q3 2021 and held it in 14 quarters. The position peaked at $25K in Q3 2021. 166 funds tracked by Wall St. Rank hold DNA as of Q2 2025.

  • Close Asset Management reported no remaining Ginkgo Bioworks position as of Q2 2025 after selling out during the quarter.
  • Close Asset Management sold 28 Ginkgo Bioworks shares in Q2 2025.
  • Close Asset Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 14 quarters.
  • Close Asset Management's Ginkgo Bioworks position peaked at $25K in Q3 2021.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2025.

Based on Close Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.